Fidelis Capital Partners’s Bio-Techne TECH Stock Holding History

Fidelis Capital Partners’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,314	Closed	-$239K	–	457
2024 Q4	$239K	Buy	3,314 +39	+1%	+$2.86K	0.02%	380
2024 Q3	$227K	Buy	+3,275	New	+$246K	0.03%	367

Other funds holding TECH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Fidelis Capital Partners's TECH Position: Q1 2025 in Review

Fidelis Capital Partners sold out of Bio-Techne (TECH) in Q1 2025, closing a stake of 3,314 shares — an estimated $239K sold.

Fidelis Capital Partners first reported a position in TECH in Q3 2024 and held it in 2 quarters. The position peaked at $239K in Q4 2024. 577 funds tracked by Wall St. Rank hold TECH as of Q1 2025.

Fidelis Capital Partners reported no remaining Bio-Techne position as of Q1 2025 after selling out during the quarter.
Fidelis Capital Partners sold 3,314 Bio-Techne shares in Q1 2025, an estimated $239K.
Fidelis Capital Partners first reported a position in Bio-Techne in Q3 2024 and held it in 2 quarters.
Fidelis Capital Partners's Bio-Techne position peaked at $239K in Q4 2024.
577 funds tracked by Wall St. Rank held Bio-Techne as of Q1 2025.

Based on Fidelis Capital Partners's 13F filing for Q1 2025, filed 1 May 2025.